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A B S T R A C T
Background: Schizoaffective disorder, bipolar type (SAD) and bipolar disorder I (BD) present a large
clinical overlap. In a 1-year follow-up, we aimed to evaluate days to hospitalization (DTH) and predictors
of relapse in a SAD-BD cohort of patients.
Methods: A 1–year, prospective, naturalistic cohort study considering DTH as primary outcome and
incidence of direct and indirect measures of psychopathological compensation as secondary outcomes.
Kaplan-Meyer survival analysis with Log-rank Mantel-Cox test compared BD/SAD subgroups as to DTH.
After bivariate analyses, Cox regression was performed to assess covariates possibly associated with DTH
in diagnostic subgroups.
Results: Of 836 screened patients, 437 were finally included (SAD = 105; BD = 332). Relapse rates in the SAD
sample was n = 26 (24.8%) vs. n = 41 (12.3%) in the BD sample (p = 0.002). Mean  SD DTH were 312.16  10.6
(SAD) vs. 337.62  4.4 (BD) days (p = 0.002). Patients with relapses showed more frequent suicide acts,
violent behaviors, and changes in pharmacological treatments (all p < 0.0005) in comparison to patients
without relapse. Patients without relapses had significantly higher mean number of treatments at T0
(p = 0.010). Cox regression model relating the association between diagnosis and DTH revealed that BD had
higher rates of suicide attempts (HR = 13.0, 95%CI = 4.0–42.0, p < 0.0005), whereas SAD had higher rates of
violent behavior during psychotic episodes (HR = 12.0, 95%CI = .3.3-43.5, p > 0.0005).
Conclusions: SAD patients relapse earlier with higher hospitalization rates and violent behavior during
psychotic episodes whereas bipolar patients have more suicide attempts. Psychiatric/psychological follow-
up visits may delay hospitalizations by closely monitoring symptoms of self- and hetero-aggression.
© 2019 Published by Elsevier Masson SAS.
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European Psychiatry
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Bipolar affective (BD) and schizoaffective (SAD) disorders are
complex, severe conditions characterized by a high degree of
clinical overlap during acute and cross-sectional evaluation, and
a chronic, relapsing longitudinal course [1]. Together with
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[2], substantial overlap with a high genetic correlation [3], and
high relative risks of developing one of these conditions among
relatives of both purely affective and psychotic patients [4].
Contrary to BD and schizophrenia, a controversial nosological
discussion [5,6], criticism over its poor diagnostic reliability [7]
and its clinical heterogeneity [8] have surrounded the SAD
diagnosis since its appearance in psychiatric diagnostic classi-
fications.
When studied in clinical settings, SAD has been generally
considered with intermediate severity, between BD and schizo-
phrenia [9], and its clinical management has suffered from an
overall lack of population-specific research, being mostly ground-
ed on extrapolations from BD or purely psychotic samples [10,11].
Despite an increase in the overall treatment options and
optimistic results from randomized controlled trials, more than
half of all BD patients relapse within 2 years, with possibility to
experience at least 1 additional acute episode during their life time
[12–14]. Similar data on SAD are scant, as fewer randomized
controlled trials and naturalistic studies have been performed so
far [15,16]. An indirect note for high relapse rates anyway is that
SAD accounted for up to one-quarter of admissions to acute units in
the past [17] and up to 31.3% in inpatients settings currently [18].
SAD and BD may seem indistinguishable in acute, cross-sectional
clinical presentation. A longitudinal diagnostic evaluation espe-
cially aimed at the persistence and overall duration of affective and
psychotic symptoms seems of paramount importance to better
define the bipolar and schizoaffective populations [19], but,
contrary to BD, clinical research on the course of illness of SAD
is scant. Luckily, the latest international classification system
introduced a more longitudinal evaluation of the time spent with
purely psychotic or affective symptoms [20], with an improved
reliability in SAD’s diagnostic stability [21], but with unclear
clinical implications.
Consequently, prospective, observational naturalistic studies
are warranted and could clarify practical implication in distin-
guishing SAD bipolar from pure BD populations, and they might
help filling the gap between the scant clinical trials and clinical
practice in SAD. Comparison with BD would be specially needed to
understand to which extent SAD may be reduced to a severe form
of BD. For this reason, we decided to follow-up a cohort of patients
followed-up in our tertiary care setting.
We hypothesized that relapsing patients would be more
frequent among the SAD population, and that SAD patients would
show a more severe clinical course, and a decreased tendency to
psychopathological compensation. For this reason, we compared
the clinical course of a cohort of BD and SAD patients followed-up
during one year, considering time to hospitalization as a main
outcome. We also considered direct (i.e. following hospitalizations,
violent behaviors and suicidal acts), and indirect (i.e. type and
number of treatments, and changes in treatments during the
follow-up) measures of psychopathological compensation. Finally,
we also evaluated possible hazards ratio associated with predictor
variables in the BD and SAD diagnostic subgroups.
2. Methods
2.1. Study design and participants
In this prospective, naturalistic cohort study we chose a priori
one year (referred to as index year, IY) in the life and course of
illness of patients enrolled, assessed and treated in the Bipolar
Disorders Unit of Barcelona, with the approval of the local ethics
committees and in accordance with the ethical principles of the
Declaration of Helsinki. [22].2.2. Inclusion/Exclusion criteria
Patients were considered for inclusion only if theirclinical history
was electronically recorded. We considered an index year (IY)
starting from the 1st of January 2015, to the 31th December 2015.
Inclusion criteria were age older than 18 years, fulfilling diagnosis for
BD type I or SAD according to DSM-IV-TR [23] and a follow-up during
at least one year. Exclusion criteria were pregnancy or no availability
of data during the IY (e.g. patients not resident in the catchment area
that had a brief contact with our Unit).
2.3. Assessment
Basic demographic information (age, gender) were extracted
from the electronic clinical history of each patient. Direct measures
of psychopathological compensation were defined a priori as the
presence of a new hospitalization, time to a new hospitalization,
total number of hospitalizations, episode type of hospitalization
(i.e. purely psychotic, nonpsychotic or psychotic manic, nonpsy-
chotic or psychotic mixed, nonpsychotic or depressed episode),
presence and number of suicidal attempts, presence and number of
violent behaviors (physical, either towards objects or people),
episode type of violent behaviors (psychotic, manic, depressive,
mixed), and number of emergency attendances for acute
symptoms not resulting in hospitalization, but not for other
reasons such as prescription renewal.
Indirect, treatment-related measures of psychopathological
compensation were defined a priori as number of “major treatment”
(definition see below) at T0 (alone, with benzodiazepines, with
other psychotropic medications), number of “major treatments” at
T1 (alone, with benzodiazepines, with other psychotropic medi-
cations), total changes in “major treatments”, total number and
change of antipsychotic medication taken in 365 days, total number
and change of mood-stabilizers taken in 365 days, total number and
change of antidepressants taken in 365 days, beginning or
discontinuation, or both beginning and discontinuation of long-
acting treatment, and treatment with electroconvulsive therapy
(ECT). “Major treatments” were defined as first- or second-line
treatments for at least 1 phase among acute mania, acute
depression, long-term treatment for BD and for SAD [24–26]. We
decided to use the same definition of “major treatment” also for SAD
patients due to the lack of clinical guidelines for SAD and the
substantial overlap in the type of drugs used [11,27].
2.4. Statistical analyses
Kaplan-Meyer survival analysis with Log-rank Mantel-Cox test
was used to compare diagnostic subgroups as to time to
hospitalization, using the overall mean time to hospitalization
as a threshold for event/censorship. Bivariate analyses were
performed with Chi-square tests, independent-samples t-test, or
Mann-Whitney U test (according to type of distribution of the
variable). Cox regression (proportional hazard analysis) was
performed in order to assess covariates possibly associated with
time to hospitalization, and including statistically significant
variables differentiating the 2 diagnostic subgroups. Statistical
analyses were performed using the Statistical Package for Social
Sciences (Statistical Package for Social Science-SPSS, 23.0 version
for Windows Inc., Chicago, IL, USA). All p values were two-tailed
and statistical significance was set at p<0.05.
3. Results
A complete flowchart showing the patients’ selection process
from computerized entries (visits) during IY to final sample
included is presented in Fig. 1.
Fig. 1. Flowchart of included patients. All electronic visit entries scanned during Index Year were attributed to a pool of patients that underwent screening for inclusion or
exclusion from the present study. BD = Bipolar disorder, type I; IY = Index Year; SAD = Schizoaffective disorder, bipolar subtype.
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study, of which 437 were finally included in the present study. Of
those, 332 fulfilled a diagnosis for BD type I disorder, 105 for SAD,
bipolar subtype. Baseline characteristics (sex and mean age) of the
diagnostic subgroups were not statistically different (see Table 1).
3.1. Relapses and time to hospitalization
SAD patients relapsed with hospitalization statistically more
frequently than BD patients SAD (n = 26/105, 24.8%) vs. BD (n = 41/
332, 12.3%), χ2 = 9.468, p = 0.002). Mean time (SD) to hospitaliza-
tion was 312.2 (10.6) days for SAD and 337.6 (4.4) days for BD.
These differences were statistically significant (Mantel Cox
χ2 = 9,421, p = 0.002) (Fig. 2).
When relapsing patients were compared according to diagnos-
tic subgroups, SAD patients showed significantly less (0, [0-0])
depressive episodes without psychotic symptoms than BD patients
(0, [0–1], U = 390.000, p = 0.004), less changes in mood-stabilizers
(SAD = 0, [0–1], BD = 0, [0–4], U = 281,500, p < 0.0001).
3.2. Direct measures of psychopathological compensation
3.2.1. All patients relapse versus non-relapse
All relapsing patients, both BD and SAD, had more emergency
attendances and suffered from more frequent suicidal acts and
violent behaviors than those without relapses (all <0.0005). A
summary of the differences between patients with or without
relapses in direct measures of psychopathological compensation is
presented in Table 2.Table 1
Baseline demographic characteristics in diagnostic subgroups.
Variables BD (n = 332) SAD (n = 105) test p
Female sex (n) 182 54.8% 58 55.2% 0.0061 0.940
Age (years) 52.89 33.09 51.17 39.32 0.4432 0.658
Notes: BD = Bipolar Disorder; SAD = Schizoaffective Disorder; SD = Standard Deviation.
Type of statistical test: 1 = Chi square test; 2 = independent-samples t-test.3.2.2. Intra-group differences
3.2.2.1. Patients without relapse. No statistically significant
differences in age or gender were found in the relapsing group
between BD and SAD patients. Globally, no statistical differences
were found between BD and SAD without relapse subgroups in
emergency attendances, suicidal or violent acts.
3.2.2.2. Patients with relapse. No statistically significant differences in
age or gender were found in the BD and SAD patients with relapse. SAD
patientswithrelapsedidnotpresenthigherhospitalizationscompared
to BD patients (1.2  0.5 vs. 1.2  0.4, ns). SAD patients predictably
presentedpsychoticrelapses,butBDpatients inchangepresentedwith
significantly more pure manic (0.3  0.5 vs. 0.0  0.2, Mann-Whitney
423.0,p = 0.028) anddepressiveepisodes(0.3  0.5 vs. 0.0  0.0 Mann-
Whitney = 390.0, p = 0.004). No significant differences in emergency
attendances, suicidal acts and violent behaviors were recorded, but
SAD patients committed more violent behaviors exclusively during
acute pure psychotic episodes (n = 6, 23.1%), whilst BD patients during
purely manic (n = 4, 9.8%) or mixed (n = 2, 4.9%) episodes.
3.3. Indirect measures of psychopathological compensation
Patients without relapse showed a significantly higher mean
numberof treatments at T0,“major” treatments (p = 0.01), combined
with benzodiazepines (p = 0.012) or total (p = 0.028). Total changes,
specific changes in antidepressants, antipsychotics and mood-
stabilizers were significantly higher in the relapsing group (all
p < 0.0005),aswell asthe total numberofantipsychotics usedduring
IY (p < 0.0005). Prevalent use and beginning of treatment with long-
acting injectable drugs were significantly higher in relapsing
patients (p = 0.005 and p < 0.0005 respectively), as well as treatment
with electroconvulsive therapy (ECT, p = 0.012) (Table 3).
3.3.1. Intra-group differences
3.3.1.1. Patients with relapse. BD patients with relapse showed
significantly more frequent changes in mood-stabilizer medication
Fig. 2. Kaplan–Meier curves for time to hospitalization. BD = Bipolar disorder, type I; SAD = Schizoaffective disorder, bipolar subtype. Relapses: SAD (n = 26/105, 24.8%) vs. BD
(n = 41/332, 13.3%), χ2 = 9.468, p = 0.002. Mean time  SD to hospitalization: SAD = 312.16  10.62 days vs. BD = 337.62  4.43 days, Mantel Cox χ2 = 9,421, p = 0.002.
Note: Hospitalization was decided when an acute exacerbation of manic, psychotic, suicidal symptoms, was present or whereas psychomotor agitation, aggressiveness and/or
lack of insight and need for treatment could impair patients’ safety.
Table 2
Differences among patients relapsing and not relapsing.
No relapse (n = 370) Relapse (n = 67)
Variables (n or mean)* (% or SD) (n or mean)* (% or SD) Test P
Female gender 202 54.6 38 56.7 0.1031 0.748
Age (years) 53.29 37.10 47.97 14.56 1.0572 0.305
Diagnoses
BD 291 78.6 41 61.2 9.4681 0.002
SAD 79 21.4 26 38.8
Emergency attendances
-Yes 22 5.9 17 25.4 26.3411 <0.0005
-Number 0.80 0.36 0.57 1.50 24732.03 <0.0005
Suicide attempts
-Yes 0 0.0 5 7.5 27.9321 <0.0005
-Number 0.00 0.00 0.07 0.27 13320.03 <0.0005
Violent behaviors
-Yes 1 0.3 11 16.4 55.3871 <0.0005
-Number 0.00 0.52 0.22 0.55 14582.53 <0.0005
-During Episode
Mania 0 0.0 4 6.0 22.2941 <0.0005
Mixed 1 0.3 6 9.0 11.0961 0.023
Psychotic 0 0.0 2 3.0 27.1471 <0.0005
Notes: BD = Bipolar Disorder type I; SAD = Schizoaffective disorder, bipolar type.
Type of statistical test: 1 = Chi square; 2 = independent-samples t-test; 3 = Mann-Whitney.
* Mann-Whitney test was used for non-parametric variables. Means and standard errors are reported in the table for descriptive purpose.
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Whitney = 355.5, p = 0.008) and an overall significantly higher
number of mood-stabilizers used during IY (1.4  0.7 vs. 0.8  0.7,
Mann-Whitney = 2.81.5, p < 0.0005).
3.3.1.2. Patients without relapse. At T0, SAD patients without
relapse showed significantly higher number of major treatments
(2.8  1.2 vs. 2.3  1.0, Mann-Whitney = 13,665.6, p = 0.007), major
treatments with benzodiazepines (3.2  1.3 vs. 2.8  1.2, Mann-
Whitney = 13.473.0, p = 0.015) and total treatments (3.6  1.6 vs.
2.9  1.3, Mann-Whitney 14.009-5, p = 0.002). At the end of IY, SAD
patients showed a significant total number of treatments (3.5  1.4
vs. 3.1 1.4, Mann-Whitney = 13.248.0, p = 0.033). No significant
differences were found in total and specific changes in
antidepressants, antipsychotics and mood-stabilizers, but SAD
patients without relapse showed a significant higher number
of antipsychotics tried during IY (1.7  0.9 vs. 1.0  0.8,Mann-Whitney 16609.5, p < 0.0005) and lower number of
mood-stabilizers tried during IY (0.9  0.7 vs. 1.2 vs. 0.6, Mann-
Whitney = 8132.0, p < 0.0005). Also, SAD without relapse were
more frequently on long-acting injectable treatment than BD
patients without relapse (15, 19.0% vs. 12, 4.1%, X2 = 20.291,
p < 0.0005)
3.4. Prediction of hospitalization by diagnostic subgroups
We performed two Cox-Regression analyses on diagnostic
subgroups in order to detect possible factors contributing to risk of
hospitalization.
3.4.1. Bipolar subgroup
Cox-Regression analysis for BD subgroup was overall
statistical significant (χ2 = 494.819, df = 10, p < 0.0005). Variables
with a single significant contribution were: suicide attempts
Table 3
Differences in indirect (treatment) measures of psychopathological compensation in diagnostic subgroups.
No Relapse (n = 370) Relapse (n = 67)
Variables (mean)* (SD) (mean)* (SD) Test
N of drugs at T0: M-W P
Major 2.41 1.07 2.04 1.17 10066.51 0.010
Major + BZD 2.85 1.23 2.45 1.41 10072.5 0.012
Total 3.08 1.40 2.72 1.71 10346.5 0.028
N of drugs at T1:
Major 2.46 1.05 2.42 0.781 12.294.0 0.911
Major + BZD 2.92 1.21 2.94 0.95 12572.0 0.847
Total 3.18 1.38 3.22 1.20 12665.6 0.770
N of Changes
Total changes 0.67 1.37 3.82 2.73 21642.0 <0.0005
- in antidepressants 0.23 0.83 0.52 0.88 14894.0 <0.0005
- in antipsychotics 0.34 2.61 2.61 2.16 21405.5 <0.0005
- in mood stabilizers 0.08 0.31 0.60 0.99 16242.5 <0.0005
Drugs tried in 365 days:
N of antidepressants 0.47 0.73 0.51 0.70 12825.5 0.595
N of antipsychotics 1.14 0.88 2.10 0.92 19198.0 <0.0005
N of mood stabilizers 1.14 0.66 1.16 0.73 12737.5 0.682
n (%) n (%) χ2 P
Long-Acting Injectable
Yes 27 7.3 12 17.9 7.861 0.005
In during the IY 6 1.6 10 14.9 28.465 <0.0005
Out during the IY 6 1.6 2 3.0 0.587 0.444
On ECT 13 3.5 7 10.4 6.246 0.012
Notes: BD = Bipolar Disorder; BZD = Benzodiazepines; ECT = Electroconvulsive Treatment; IY = Index Year; N = Number; SAD = Schizoaffective Disorder; T0 = Beginning of IY; T1 =
Conclusion of IY.
Tests: M–W = Mann-Whitney test; χ2= Chi square test.
* Mann-Whitney test was used for non-parametric variables. Means and standard errors are reported in the table for descriptive purpose.
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in IY (HR = 12.5, 95%CI = 5.7–23.0, p < 0.0005), purely depressed
first relapse in IY (HR = 9.8, 95%CI = 4.2–23.0, p < 0.0005), violent
behavior during mixed phase (HR = 9.1, 95%CI = 1.8–45.4,
p = 0.007), violent behavior during manic phase (HR = 6.8, 95%
CI = 2.3–20.8, p = 0.001), total number of antipsychotics tried in IY
(HR = 1.5, 95%CI = 1.1–2.2, p = 0.025), total number of emergency
attendances (HR = 1.5, 95%CI = 1.2–1.8, p = 0.050), and changes in
antipsychotics (HR = 1.3, 95%CI = 1.1–1.6, p = 0.003).
3.4.2. Schizoaffective subgroup
Cox-Regression analysis for SAD subgroup was overall
statistical significant (χ2 = 357.845, df = 9, p < 0.0005). Variables
with a single significant contribution were: violent behavior
during purely psychotic phase (HR = 12.1, 95%CI = 3.3–43.5,
p > 0.0005), purely psychotic first relapse in IY (HR = 9.9, 95%
CI = 4.0–24.7, p < 0.0005), suicide attempts (HR = 9.1, 95%
CI = 2.7–30.7, p < 0.0005), changes in antipsychotics (HR = 1.6,
95%CI = 1.3–1.9, p < 0.0005), total number of emergency attend-
ances (HR = 1.5, 95%CI = 1.2–1.9, p < 0.0005), and total drugs at
T0 (HR = 1.3, 95%CI = 1.1–1.5).
4. Discussion
Our prospective naturalistic 1-year follow-up study comparing
BD with SAD patients revealed some clinical relevant results. First of
all, the hospitalization rate during the one-year follow-up was
significantly higher in the SAD sample than in the BD subgroup
(24.8%vs.12.3%). Secondly, whenrelapsing, thediagnosticsubgroups
did not present differences in overall number of hospitalizations, yet
SAD almost invariantly relapsed into psychotic episodes, while BD
patients more frequently into pure mania and depression. Overall,
SAD and BD subgroups seem to confirm a differential severity in the
course of illness measured as time to hospitalization and acute
clinical exacerbation, with SAD being the more severe condition. Yet,
these diagnostic labels may be not informative on the actualprognosis of the patients. Thirdly and as expected, all patients with a
relapse presented statistically more frequently signs of psychopath-
ological unbalance such as suicide attempts, emergency attend-
ances, and violent behaviors. Subpopulations at risk for worst
outcomes should be defined in order to improve the prognostic value
of a diagnosis. For instance, a careful evaluation of symptom
dimensions would allow for better defining, addressing and
managing critical treatment targets [28,29].
Furthermore, hetero-aggressiveness with violent behaviors
played a major role in predicting hospitalization in our sample, as
SAD patients presenting violent behaviors during a purely
psychotic episode had a 12-fold increased risk to hospitalization,
while BD present a 9-fold increased risk when presenting violent
behaviors during mixed phase and 6-fold increased risk when
presenting violent behaviors during manic phase. According to
national surveys, the prevalence of violence in the general
population is about 2% while it ranges from 0.8 to 34.7% in
samples including individuals with mental illness, depending on
the psychiatric disorder considered [30]. The relevance of
aggressiveness as a cross-diagnostic negative prognostic factor
finds ground on its frequent association with BD, especially in
acute mixed phases [31], and it seems an even more important
factor in SAD populations [32]. Common shared genetic liability
could be hypothesized, as, for instance, neuronal splicing
regulator RBFOX1 has been found associated to BD [33] as well
as schizophrenia [34], and, more recently, to violent aggressive
behavior [35]. On the other hand, it is possible that biological
bases underpinning aggressive behavior only partially relate with
a clinical syndrome, e.g. psychosis. A recent study outlined that
lower levels of morning cortisol and cortisol variability signifi-
cantly related to both aggression and psychosis, but indepen-
dently, and no correlation with age, gender or psychosis severity
or duration [36]. In this sense, categorical diagnoses predictably
show a limited predictive validity, and the clinical assessment of
patients could benefit from a different type of stratification
considering, for instance, high levels of impulsivity, hostility,
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low social functioning [37].
In our study, self-aggressiveness also plays a major role in
predicting hospitalization. SAD patients presented in our
sample a 9-fold increased risk for hospitalization while BD
patients presented a 13-fold increased risk when presenting
suicidal acts. Conceptualization of suicide and aggressive/
violent acts tends to a semantic similarity, framing these
behaviors as self- and hetero- aggressiveness. A partial overlap
in clinical presentation, with a possible predictive role of
hetero-aggressiveness for suicidality, is possible [38] and could
recognize a shared liability for impulsivity [39,40]. Yet, these
behaviors could also derive from different symptoms dimen-
sions, as well as genetic or biological mechanisms [41].
Interestingly, violent behaviors occurred only during acute
episodes in our study. This has to be emphasized, and seems
reinforced when considering the struggle for symptom control. In
fact, relapsing patients presented more frequent changes in overall
major treatments. Interestingly, patients not relapsing during IY
presented a higher number of treatments at T0. In our regression
models, both diagnostic subgroups presented more frequent
changes in antipsychotic medications (and total antipsychotics
tried in IY in bipolar subsample). Notably, average drug combi-
nations in our study fall far beyond clinical guidelines recom-
mendations [42,43]. The high rates of relapses in SAD populations
might derive from the severity of the disease or from the lack of
efficacy of current treatment options, undetected by pure
populations recruited in randomized clinical trials. Also, it is
possible that the frequent use of polypharmacy combinations
stretching beyond evidence-based practices, produces complex
interactions [44,45]. In the real-world, there is a clinical need for
specifically tailored treatment plans, paradoxically and unani-
mously suggested by the very same guidelines.
On the other hand, past studies agree on the need for proper
symptomatic and clinical management for better illness and
overall health outcomes [46], but mortality rates in severe mental
illness could derive from iatrogenic effects [47] as well as from an
under-prescription for other comorbid medical conditions [48,49].
So, caution must be called for the risk of cumulative prescription
and subsequent overtreatment [24].
When considering the role of aggressiveness in our study,
evidence supports a benefit of second-generation antipsychotic
medication in its management in psychotic conditions, with no
apparent influence of mood-stabilizers or antidepressants [50,51],
yet the benefit of beginning or suspending of the latter may clearly
relate to acute mood prevention that in our sample invariably
associated with such behavior [52].
Stabilized, SAD patients without relapse presented higher
number of tried and actual treatments compared to BD patients
without relapse. The use of long-acting injectable antipsychotics
failed to ensure a good control of symptomatology in our study,
which is in accordance with previous data that reported increased
odds for relapse despite of an evidence of their efficacy [53]. This
apparent contradiction could result from a selection bias for
candidates to these treatments, tolerability issues, or anyway an
improvement compared to previous course of illness for these
patients. Unluckily, the design of our study did not allow for a
throughout analysis of this aspect.
Lastly, we found in our study that frequent emergency
attendances constitute a clear signal of increased risk for acute
relapse. It is possible that psychosocial interventions aimed at an
improving insight and awareness in patients and caregivers alike
contribute to this effect [54,55]. Hereby, patients might benefit
from further psychosocial/psychotherapeutic interventions aimed
at encompassing cognitive deficits in a preventive way [56],
impaired functioning [57], or untreated adverse events [58].Some limitations of our work have to be taken into consider-
ation. In order to minimize selection bias, the choice of the Index
Year was performed a priori. Yet, a selection bias may not be
excluded. Another limitation is the choice of considering a change
of treatment as a measure of psychopathological compensation, as
to say of efficacy, whilst it may also represent a measure of
tolerability of the treatments prescribed. However, this possible
bias was true for both BD and SAD diagnostic subgroups. Average
doses of drugs used would have been ideal, yet the overall sample
size did not allow for a dose-specific analysis. Recollection of other
variables would have been also informative (e.g., number and type
of previous episodes), but data were not collected in the clinical
corresponding histories.
Compared to BD, SAD patients present a more severe course of
illness measured as time to hospitalization. Violent acts towards
selves (BD) or others (SAD) strongly predict a worse course of illness
and may representstrategic therapeutictargets. Interventions aimed
at improving patients’ and caregivers’ awareness on the disorder
should be systematically implemented, as increased emergency
attendances signal at-risk situations and would possibly allow for
recurrence prevention. Increased emergency attendances should
call for optimized combination treatments, warranting an improved
control over symptoms, thus delaying hospitalizations.
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